Literature DB >> 9338647

Protection of rat spinal cord from ischemia with dextrorphan and cycloheximide: effects on necrosis and apoptosis.

H Kato1, G K Kanellopoulos, S Matsuo, Y J Wu, M F Jacquin, C Y Hsu, D W Choi, N T Kouchoukos.   

Abstract

OBJECTIVE: We examined the characteristics of neuronal cell death after transient spinal cord ischemia in the rat and the effects of an N-methyl-D-aspartate antagonist, dextrorphan, and a protein synthesis inhibitor, cycloheximide.
METHODS: Spinal cord ischemia was induced for 15 minutes in Long-Evans rats with use of a 2F Fogarty catheter, which was passed through the left carotid artery and occluded the descending aorta, combined with a blood volume reduction distal to the occlusion. The rats were killed after 1, 2, and 7 days. Other groups of rats were pretreated with dextrorphan (30 mg/kg, intraperitoneally, n = 7), cycloheximide (30 mg, intrathecally, n = 7), or vehicle (saline solution, n = 12) and killed after 2 days.
RESULTS: This model reliably produced paraplegia and histopathologically distinct morphologic changes consistent with necrosis or apoptosis by light and electron microscopic criteria in different neuronal populations in the lumbar cord. Scattered necrotic neurons were seen in the intermediate gray matter (laminae 3 to 7) after 1, 2, and 7 days, whereas apoptotic neurons were seen in the dorsal horn laminae 1 to 3 after 1 and 2 days. Deoxyribonucleic acid extracted from lumbar cord showed internucleosomal fragmentation (laddering) on gel electrophoresis indicative of apoptosis. The severity of paraplegia in the rats treated with dextrorphan and cycloheximide was attenuated 1 day and 2 days after ischemia. The numbers of both necrotic and apoptotic neurons were markedly reduced in both dextrorphan- and cycloheximide-treated rats.
CONCLUSIONS: The results suggest that both N-methyl-D-aspartate receptor-mediated excitotoxicity and apoptosis contribute to spinal cord neuronal death after ischemia and that pharmacologic treatments directed at blocking both of these processes may have therapeutic utility in reducing spinal cord ischemic injury.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9338647     DOI: 10.1016/S0022-5223(97)70051-5

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Fas receptor and neuronal cell death after spinal cord ischemia.

Authors:  K Matsushita; Y Wu; J Qiu; L Lang-Lazdunski; L Hirt; C Waeber; B T Hyman; J Yuan; M A Moskowitz
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

2.  Expression of arginyl-tRNA synthetase in rats with focal cerebral ischemia.

Authors:  Rong Fu; Yun-Zhi Fan; Yu-Cong Fan; Hong-Yang Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

Review 3.  Delayed cell death signaling in traumatized central nervous system: hypoxia.

Authors:  Danielle Chu; JingXin Qiu; Marjorie Grafe; Roderick Fabian; Thomas A Kent; David Rassin; Olivera Nesic; Karin Werrbach-Perez; Regino Perez-Polo
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

4.  Hypothermic circulatory arrest and hypothermic perfusion for extensive disease of the thoracic and thoracoabdominal aorta.

Authors:  N T Kouchoukos
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-01

5.  [Glutamate neurotoxicity during spinal cord ischemia--neuroprotective effects of glutamate receptor antagonists].

Authors:  T Nakamichi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-09

6.  The selective poly(ADP)ribose-polymerase 1 inhibitor INO1001 reduces spinal cord injury during porcine aortic cross-clamping-induced ischemia/reperfusion injury.

Authors:  Christian Maier; Angelika Scheuerle; Balázs Hauser; Hubert Schelzig; Csaba Szabó; Peter Radermacher; Jochen Kick
Journal:  Intensive Care Med       Date:  2007-03-15       Impact factor: 17.440

7.  Global gene expression profiling of ischemic preconditioning in the rat retina.

Authors:  W Kamphuis; F Dijk; S van Soest; A A B Bergen
Journal:  Mol Vis       Date:  2007-06-28       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.